Restoring patency to central venous access devices

Clinical Journal of Oncology Nursing

Volumn 12, Issue 6, 2008, Pages 925-934

  Cummings Winfield, Cynthia ^a   Mushani Kanji, Tayreez ^a  

^a CROSS CANCER INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; CENTRAL VENOUS CATHETERIZATION; ECONOMICS; FIBRINOLYTIC THERAPY; HUMAN; NEOPLASM; NURSING; THROMBOSIS;

ADULT; CATHETERIZATION, CENTRAL VENOUS; HUMANS; NEOPLASMS; THROMBOLYTIC THERAPY; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 58949084945     PISSN: 10921095     EISSN: 1538067X     Source Type: Journal    
DOI: 10.1188/08.CJON.925-934     Document Type: Article

References (39)

1. ® Pédiatrie Study). Journal of Vascular and Interventional Radiology, 77(11, Pt.l), 1745-1751.
2. Cancer Care Ontario. (2007). Cancer as a chronic disease: Implications for health care in Ontario. Retrieved July 2007, from http://www.cancercare.on.ca/AGM2007Presentation/AGMPresentation-MASTERApril25ts.ppt
3. Deitcher, S.R., Fesen, M.R., Kiproff, P.M., Hill, PA., Li, X., McClus-key, E.R., et al. (2002). Safety and efficacy of alteplase for restoring function in occluded central venous catheters: Results of the Cardiovascular Thrombolytic to Open Occluded Lines Trial. Journal of Clinical Oncology, 20(1), 317-324.
4. Dudrick, S.J. (2006). History of vascular access. Journal ofParen-teral and Enterai Nutrition, 30(1, Suppl.), S47-S56.
5. Fedan, J.S. (2003). Anticoagulant, antiplatelet, and fibrinolytic (thrombolytic) drugs. In C.R. Craig & R.E. Stitzel (Eds.), Modern pharmacology with clinical applications (6th éd., pp. 269-278). Lippincott Williams and Wilkins.
6. Forauer, A.R., & Theoharis, C. (2003). Histologie changes in the human vein wall adjacent to indwelling central venous catheters. Journal of Vascular and Interventional Radiology, 14(9, Pt. 1), 1163-1168.
7. Galloway, S., & Bodenham, A. (2004). Long-term central venous access. British Journal of Anaesthesia, 92(5), 722-734.
8. ® [Product insert]. South San Francisco, CA: Author.
9. Grunfeld, E. (2006). Looking beyond survival: How are we looking at survivorship? Journal of Clinical Oncology, 24(32), 5166-5169.
10. Hadaway, L.C. (2005). Reopen the pipeline for I.V. therapy. Nursing, 35(8), 54-61.
11. Haire, W.D., Atkinson, J.B., Stephens, L.C, & Kotulak, G.D. (1994). Urokinase versus recombinant tissue plasminogen activator in thrombosed central venous catheters: A double-blinded, randomized trial. Thrombosis andHaemostasis, 72(4), 543-547
12. Haire, W.D., Deitcher, S.R., Mullane, K.M., Jaff, M.R., Firszt, CM., Schulz, G.A., et al. (2004). Recombinant urokinase for restoration of patency in occluded central venous access devices: A double-blind, placebo-controlled trial. Thrombosis and Haemostasis, 92(3), 575-582.
13. Hamilton, H. (2006a). Complications associated with venous access devices: Part one. Nursing Standard, 20(26), 43-50.
14. Hamilton, H. (2006b). Complications associated with venous access devices: Part two. Nursing Standard, 20(27), 59-65.
15. Home, M.K., III. (2004). Thrombolytics for occluded catheters. Critical Care Medicine, 32(10), 2146-2147
16. Hurtubise, M.R., Bottino, J.C, Lawson, M., & McCredie, K.B. (1980). Restoring patency of occluded central venous catheters. Archives of Surgery, 115(2), 212-213.
17. Infusion Nurses Society. (2006). Policies and procedures for infusion nursing (3rd éd.). Norwood, MA: Infusion Nurses Society
18. Jacobs, B.R. (2003). Central venous catheter occlusion and thrombosis. Critical Care Clinics, 19(3), 489-514.
19. Jacobs, B.R., Haygood, M., & Hingl, J. (2001). Recombinant tissue plasminogen activator in the treatment of central venous catheter occlusion in children. Journal of Pediatrics, 139(4), 593-596.
20. Journeycake, J.M., & Buchanan, G.R. (2006). Catheter-related deep venous thrombosis and other catheter complications in children with cancer. Journal of Clinical Oncology, 24(28), 4575-4580.
21. Kerner, J.A., Jr., Garcia-Careaga, M.G., Fisher, A.A., & Poole, R.L. (2006). Treatment of catheter occlusion in pédiatrie patients. Journal of Parenteral and Enterai Nutrition, 30(1, Suppl.), S73-S81.
22. Kokotis, K. (2005). Cost containment and infusion services. Journal of Infusion Nursing, 28(3, Suppl.), S22-S32.
23. Liu, C.Y., Jain, V., Shields, A.F., & Heilbrun, L.K. (2004). Efficacy and safety of reteplase for central venous catheter occlusion in patients with cancer. Journal of Vascular and Interventional Radiology, 15(1, Pt. 1), 39-44.
24. Maki, D.G., Stolz, S.M., Wheeler, S., & Mermel, L.A. (1997). Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter. A randomized, controlled trial. Annals of Internal Medicine, 127(4), 257-266.
25. ®). Clinical Journal of Oncology Nursing, 8(4), 417-418.
26. Moll, S., Kenyon, P., Bertoli, L., De Maio, J., Homesley, H., & Deitch-er, S.R. (2006). Phase II trial of alfimeprase, a novel-acting fibrin degradation agent, for occluded central venous access devices. Journal of Clinical Oncology, 24(19), 3056-3060.
27. Moureau, N., Poole, S., Murdock, M.A., Gray, S.M., & Semba, C.P (2002). Central venous catheters in home infusion care: Outcomes analysis in 50,470 patients. Journal of Vascular and Interventional Radiology, 13(10), 1009-1016.
28. Ng, R., Li, X., Tu, T., & Semba, C.P. (2004). Alteplase for treatment of occluded peripherally inserted central catheters: Safety and efficacy in 240 patients. Journal of Vascular and Interventional Radiology, 15(1, Pt. 1), 45-49.
29. Oncology Nursing Society. (2004). Access device guidelines (2nd éd.). Pittsburgh, PA: Author
30. Ottawa Hospital. (2006, July). Central venous access device (CVAD): Restoring patency for thrombotic occlusion. Nursing policy, procedure, protocol manual. Ottawa, Canada: Author.
31. Prandoni, P., Piccioli, A., & Griolami, A. (1999). Cancer and venous thromboembolism: An overview. Haematologica, 84(5), 437-445.
32. Ponec, D., Irwin, D., Haire, W.D., Hill, PA., Li, X., & McCluskey, E.R. (2001). Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: A double-blind placebo-controlled trial-The Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial. Journal of Vascular and Interventional Radiology, 12(8), 951-955.
33. Registered Nurses Association of Ontario. (2002). Toolkit: Implementation of clinical practice guidelines. Retrieved December 1, 2006, from http://www.rnao.org/Storage/12/668_BPG_Tool-kit.pdf
34. Registered Nurses Association of Ontario. (2004). Assessment and device selection for vascular access. Retrieved May 1, 2007, from http://www.rnao.org/Storage/ll/531_BPG_assess_device_se-lect_vascular.pdf
35. Registered Nurses Association of Ontario. (2005). Care and maintenance to reduce vascular access complications. Toronto, Canada: Author
36. Shen, V., Li, X., Murdock, M., Resnansky, L., McCluskey, E.R., & Semba, C.P. (2003). Recombinant tissue plasminogen activator (alteplase) for restoration of function to occluded central venous catheters in pédiatrie patients. Journal of Pédiatrie Hematol-ogy/Oncology, 25(1), 38-45.
37. Steiger, E. (2006). Dysfunction and thrombotic complications of vascular access devices. Journal of Parenteral and Enterai Nutrition, 30(1, Suppl.), S70-S72.
38. Valji, K. (2000). Evolving strategies for thrombolytic therapy of peripheral vascular occlusion. Journal of Vascular and Interventional Radiology, 11(4), 411-420.
39. Wingerter, L. (2003). Vascular access device thrombosis. Clinical Journal of Oncology Nursing, 7(3), 345-348.